Key result
Targeted overexpression of elafin protected mice against viral myocarditis, reducing 11-day mortality to 1 of 9 transgenic mice compared with 10 of 12 nontransgenic littermates.
Why the study?
Does targeted overexpression of elafin prevent mortality and cardiac dysfunction in mice following viral myocarditis?
Does targeted overexpression of elafin prevent mortality and cardiac dysfunction in mice following viral myocarditis?
Targeted overexpression of elafin in the cardiovascular system significantly reduces mortality and preserves cardiac function in a murine model of viral myocarditis.
Answers are grounded in this paper and cite their sources.
Elafin overexpression protects against myocarditis-induced cardiac injury in mice; leaves open whether elastase inhibition merits human investigation.
Serine elastases degrade elastin, stimulate vascular smooth muscle cell migration and proliferation, and are associated with myocardial damage. To evaluate the impact of elastase inhibition on cardiovascular development and disease, transgenic mice were created in which the mouse preproendothelin-1 promoter was used to target elafin overexpression to the cardiovascular system. To distinguish the transgene from endogenous elafin, constructs were made incorporating a FLAG sequence; the COOH-terminus FLAG-tagged elafin construct produced a stable, functionally active gene product and was used to create transgenic mice. Consistent with endothelin expression, abundant elafin mRNA was observed in transgenic F1 embryos (embryonic day 13.5) and in adult transgenic mice heart, trachea, aorta, kidney, lung, and skin, but not in liver, spleen, and intestine. Functional activity of the transgene was confirmed by heightened myocardial elastase inhibitory activity. No tissue abnormalities were detected by light microscopy or elastin content. However, injection of 10 plaque-forming units (PFU) of encephalomyocarditis virus resulted in death within 11 days in 10 out of 12 nontransgenic mice compared with one out of nine transgenic littermates. This reduced mortality was associated with better cardiac function and less myocardial inflammatory damage. Thus, elafin expression may confer a protective advantage in myocarditis and other inflammatory diseases.
No takes yet. Share an insight, caveat, or question.
Zaidi et al. (1999) studied Viral myocarditis (n=21). Targeted overexpression of elafin vs. Nontransgenic littermates was evaluated on Mortality within 11 days. Targeted overexpression of elafin protected mice against viral myocarditis, reducing 11-day mortality to 1 of 9 transgenic mice compared with 10 of 12 nontransgenic littermates.
Synapse has enriched 10 related papers. Consider them for comparative context: